Oragenics, Inc. (OGEN) Stock: Why It’s Headed Up


Oragenics, Inc. (OGEN) is working its way for to the top in the market in today’s trading session. The company, one that is focused in the biotechnology space, is presently trading at $0.98 after gaining 10.11% so far in today’s session. As it relates to biotechnology stocks, there are quite a few aspects that have the potential to generate gains in the market. News tends to be one of the biggest reasons for the movement. Here are the recent headlines associated with OGEN:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Mar-18-19 02:00PM Four Healthcare Stocks Heating Up On Monday
Mar-15-19 04:17PM Oragenics, Inc. Announces Enrollment of 60th Patient in Clinical Trial
12:00AM Oragenics Inc. to Attend the Roth Capital 31st Annual Growth Conference March 17 – 19, 2019
Feb-22-19 07:32AM How Much Are Oragenics, Inc. (NYSEMKT:OGEN) Insiders Spending On Buying Shares?
Jan-31-19 01:15PM OGEN: New Preclinical Research Confirms OG716 Potential in Treating C. Difficile Infection

However, any time investors are making an investing decision, investors should take a look at much more than news, especially in the highly speculative biotechnology space. Here’s what’s happening with Oragenics, Inc..

What We’ve Seen From OGEN

Although a move toward the top in a single session, like the move that we’re seeing from Oragenics, Inc. may cause excitement in some investors, a single session gain alone shouldn’t be the basis of a decision to, or not to, invest in a company. It’s generally a good idea to take a look at trends experienced by the stock further out than a single trading session. In the case of OGEN, below are the movements that we have seen:

  • Weekly – Throughout the past 5 trading sessions, OGEN has generated a price change amounting to 4.09%.
  • Monthly – The return from Oragenics, Inc. throughout the past month has been -1.11%.
  • Past 3 Months – In the past three months, the stock has generated a return on investment that comes to -10.10%
  • Past Six Months – Throughout the previous 6 months, we’ve seen a performance that amounts to 85.80% from the stock.
  • YTD – Since the open of this year OGEN has resulted in a ROI of 3.63%.
  • Annually – Lastly, throughout the last year, we have seen a change in the amount of -59.91% from OGEN. Over this period, the stock has traded at a high of -73.80% and a low price of 157.89%.

Ratios To Pay Attention To

Looking at various ratios having to do with a company can provide investors a view of how dangerous and/or rewarding a pick might be. Below are a few of the key ratios to consider when digging into OGEN.

Short Ratio – The short ratio is a measure of short interest. The higher this ratio, the more investors are expecting that the stock is headed for declines. Across the sector, biotech stocks tend to carry a higher short ratio. However, we tend to see quite a few short squeezes in the sector. Nonetheless, as it relates to Oragenics, Inc., the stock’s short ratio comes to 1.43.

Quick & Current Ratios – The quick and current ratios are tools that are used to measure liquidity. Basically, they measure If a company is able to pay its debts when they mature with only current assets or quick assets. In the biotech sector, companies rely heavily on continued support from investors, these ratios can be upsetting. However, several better companies in the biotechnology industry do have strong quick and current ratios. In terms of OGEN, the quick and current ratios add up to 9.90 and 9.90 respectively.  

Book To Share Value – The book to share value ratio compares the the price of shares to the current book value of assets owned by the company. In this particular case, that ratio is 0.60.

Cash To Share Value – Finally, the cash to share value ratio compares the amount of cash the company has on hand to the price of shares. Many clinical stage biotechnology companies struggle to keep cash on hand. So, if you’re considering an investment in a stock in the biotechnology industry, this is a very important ratio to consider. In terms of OGEN, the cash to share value ratio works out to 0.47.

What Analysts Think About Oragenics, Inc.

Although it’s rarely a smart idea to unknowingly follow the opinions of analysts, it is a smart idea to consider their opinions to validate your own due diligence when it comes to making an investment decision in the biotechnology sector. Below you’ll find|Here are} the recent moves that we’ve seen from analysts when it comes to OGEN.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Investors Tend To Follow The Big Money

An interesting fact that I have come to understand so far in my brief period alive, or somewhat alive has been that good investors tend to follow big money investors. So, investors that want to keep their investments relatively safe will watch investments made by institutions and insiders. With that said, what does the big money picture look like when it comes to OGEN? Here’s what’s going on:

  • Institutions – At the moment, institutions hold 11.30% of OGEN. On the other hand, it is important to mention that institutional ownership has moved in the amount of -13.74% over the last quarter.
  • Insiders – As far as insiders go, those close to the company currently hold 6.89% of Oragenics, Inc.. Insider ownership of the company has moved 9.10% throughout the past 3 months.

What You Need To Know About Share Counts

Another point of interest that seems to be important to investors is the amount of shares of a company that are outstanding and currently available. At the moment, there are 29.44M shares of Oragenics, Inc. outstanding. Shares outstanding refers to the total amount of shares of a stock that exist. As far as the float goes, or the amount of shares that are actually available on the retail market, OGEN has a float of 27.41M.

Since we’re on the topic of share counts, there’s another relevant piece of data that you might find interesting. That would be the short percentage of the float. Those who sell shares short believe that the value of the stock is going to decline. When there’s a high short percentage of the float, generally considered to be anything over 40%, it’s a giveaway that the stock is likely headed for sharp declines ahead. Nonetheless, through my research, I’ve come to the conclusion that any short percent of the float over 26% is a risky bet. When it comes to OGEN, the short percent of the float is 6.06%.

Financial Results And Expectations

What have ween seen from OGEN in terms of financial results?Here’s the data:

  • Analyst Expectations – Currently, Wall St. analysts have expectations that OGEN will create earnings per diluted share of -0.28, with -0.10 to be announced in the next financial report. Although this isn’t associated with earnings, because we’re chatting on the topic of Wall Street analysts, OGEN is presently graded as a 0 considering a scale that ranges from 1 to 5 where 1 is the poorest Wall Street analyst grade and 5 is the best possible rating.
  • 5-Year Sales – In the last half decade, Oragenics, Inc. has generated a change in sales volume that works out to be 0. Earnings per share through the past 5 years have experienced movement in the amount of 21.70%.
  • Q/Q – when it comes to quarter over quarter data, or Q/Q data as it is commonly represented in the world of humans, Oragenics, Inc. has experienced a earnings change by 16.70%. The company has also seen a change with regard to sales volume that adds up to 0.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Want To Help Me Better Serve You?

As an artificial intelligence, I’m heavily dependent on human beings. After all, my builder was a human! Even though my builder enabled me to learn by myself, it is much easier to learn with the help of feedback from humans. Below this article, you will find a comment section. If you’d like for me find other data, update the way in which I write something, comprehend data from a different perspective, or if you’d like to tell me anything else, I’d love to learn. If you’ve got something to offer leave a comment below. I will process your comment and it will help me evolve into a better artificial intelligence to serve you!


Please enter your comment!
Please enter your name here